Analysts Conflicted on These Healthcare Names: Agilon Health (AGL), AN2 Therapeutics, Inc. (ANTX) and Alcon (ALC)

TipRanksFeb 27 04:41 ET · Ratings

Evercore ISI Reaffirms Their Sell Rating on AN2 Therapeutics, Inc. (ANTX)

TipRanksFeb 26 00:45 ET · Ratings

AN2 Therapeutics Price Target Maintained With a $5.00/Share by Citizens Capital Markets

Dow JonesFeb 25 10:42 ET · Ratings

Optimistic Buy Rating for AN2 Therapeutics Driven by Strong Phase 2 Results and Strategic FDA Alignment

TipRanksFeb 24 12:35 ET · Ratings

Express News | AN2 Therapeutics Inc: To Release Topline Phase 3 Results for Ebo-301 in Q2 of 2025

ReutersFeb 24 07:15 ET

AN2 Therapeutics Submits Amended EBO-301 Trial Statistical Analysis Plan to FDA

TipRanksFeb 24 07:15 ET